Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies
Recruiting
Phase 2
Interventional Study
Disease-free Survival
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 55 – 65
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 61 (estimated)
- Sponsor
- Shanghai Jiao Tong University School of Medicine · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML \>=55 years.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age 55-65
* patients with HLA-matched sibling donors, 9-10/10 matched unrelated donors or haplo-identical donors.
* patients with AML in remission, or MDS in any stage, or CMML in any stage
* inform consent provided
Exclusion Criteria:
* patients with abnormal liver (\>3N), …
Contacts